Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 20Carcinoma, Hepatocellular 18Breast Neoplasms 16Small Cell Lung Carcinoma 14Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Liver Neoplasms 7Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Endometrial Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Melanoma 4Colorectal Neoplasms 4Cholangiocarcinoma 4Prostatic Neoplasms 3Neoplasms by Site 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Turcot syndrome 2Thyroid Neoplasms 2Thoracic Neoplasms 2

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Tiragolumab 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urothelial Cancer × durvalumab × Clear all
NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡